Adcitris 50mg Injection (Brentuximab) Imported

Adcitris 50mg Injection (Brentuximab) Imported

 24,500

Buy Adcitris 50mg Injection (Brentuximab Vedotin, Imported) for Hodgkin and T-cell lymphomas. Order Original medicine with safe delivery across Pakistan.

Adcitris 50mg Injection (Brentuximab) Imported

 24,500

Add to cart
Buy Now

Adcitris 50mg Injection (Brentuximab Vedotin, Imported)

Overview

Adcitris is an advanced antibody-drug conjugate (ADC) designed for targeted cancer treatment. Each vial contains 50mg of Brentuximab Vedotin as a lyophilized powder, reconstituted and given through intravenous infusion over 30 minutes. It specifically targets CD30-positive cancer cells, delivering cancer-killing medicine directly into them while minimizing harm to healthy cells.


Indications

Adcitris is used for the treatment of:

  • Relapsed or refractory Hodgkin lymphoma, especially after stem cell transplant or failed chemotherapy.

  • Systemic anaplastic large cell lymphoma (sALCL) in patients not responding to standard therapy.

  • First-line treatment of advanced Hodgkin lymphoma (Stage III/IV), usually in combination with chemotherapy.

  • Certain CD30-positive T-cell lymphomas, such as primary cutaneous ALCL and peripheral T-cell lymphoma.


Dosage & Administration

  • Standard Dose (Monotherapy): 1.8mg/kg (up to 180mg maximum) once every 3 weeks.

  • Combination Therapy (Advanced Hodgkin Lymphoma): 1.2mg/kg (up to 120mg maximum) every 2 weeks.

  • Administered only under medical supervision as an intravenous infusion.

  • Dose adjustments may be required based on liver, kidney function, or patient tolerance.


Warnings & Precautions

  • Peripheral Neuropathy: Tingling, numbness, or weakness may occur with repeated doses.

  • Infusion Reactions: Some patients may develop allergic or severe reactions during infusion.

  • Hematologic Effects: Low white blood cells, anemia, or thrombocytopenia may occur; regular blood tests are required.

  • Infections: Increased risk of bacterial, viral, or fungal infections.

  • Liver & Lung Toxicity: Monitor for breathing difficulty or abnormal liver function tests.

  • Severe Skin Reactions: Rare but possible (Stevens-Johnson syndrome, TEN).

  • Pregnancy & Breastfeeding: Not recommended during pregnancy or while nursing.


Common Side Effects

  • Fatigue, fever, nausea, diarrhea, vomiting.

  • Skin rash or itching.

  • Cough, shortness of breath.

  • Decreased appetite, weight loss.

  • Neuropathy (numbness, tingling in hands/feet).

  • Low blood counts (neutropenia, anemia, thrombocytopenia).


Storage Instructions

  • Store vials in a refrigerator (2–8°C).

  • Protect from direct sunlight and moisture.

  • Reconstituted solution should be used immediately or within the timeframe recommended by the manufacturer.


Summary Table

Attribute Details
Brand Name Adcitris (Brentuximab Vedotin), Imported
Strength 50mg single-use vial
Indication Hodgkin lymphoma, sALCL, CD30+ T-cell lymphomas
Dosage 1.8mg/kg every 3 weeks (monotherapy); 1.2mg/kg every 2 weeks (combo)
Route Intravenous infusion (30 minutes)
Side Effects Neuropathy, fatigue, nausea, fever, infections, low blood counts
Storage Refrigerated, 2–8°C, protect from light and moisture

Meta Description (160 characters):

Weight 0.1 kg